Please provide your email address to receive an email when new articles are posted on . The FDA issued a warning in 2019 about serious breathing problems associated with gabapentinoids. The study ...

Gabapentinoid use in patients with chronic obstructive pulmonary disease (COPD) was associated with a higher risk for severe exacerbations, a population-based cohort study from Canada indicated. Among ...

In May, we reported on positive phase III trial data on dupilumab (Dupixent) for uncontrolled chronic obstructive pulmonary disease, a condition with no approved biologic therapy. In this report, we ...

Severe COPD exacerbations are pivotal for both respiratory decline and cardiovascular vulnerability, with increased medication use post-exacerbation. Cardiovascular events occurred in 18.5% of ...

Compared with placebo, the time to first moderate or severe exacerbation was longer with mepolizumab. HealthDay News — For patients with chronic obstructive pulmonary disease (COPD) with a history of ...

In some patients with chronic obstructive pulmonary disease (COPD), type 2 inflammation may increase exacerbation risk and may be indicated by elevated blood eosinophil counts. Dupilumab, a fully ...

Patients with both chronic obstructive pulmonary disease (COPD) and severe pain are at an almost 40% predicted probability of falling, indicating the potential interaction between the conditions.

Sanofi and Regeneron’s Dupixent appears set up for a key FDA approval this summer for chronic obstructive pulmonary disorder (COPD). But a second biologic treatment could be on its heels in the ...

Pulmonary function tests are a group of noninvasive breathing tests that measure how much air your lungs can hold, how quickly you can move air in and out and how efficiently your lungs transfer ...